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ABSTRACT
Fertility intentions are thought to be dynamic among women of reproductive age, yet few studies
have assessed fertility intentions over time among women with HIV. We examine temporal patterns
of fertility intentions in women with HIV to assess the extent to which fertility intentions – and the
corresponding need for safer conception and judicious antiretroviral therapy (ART) regimen
selection – vary over time. 850 non-pregnant HIV-positive women aged 18–35 on or being
initiated onto ART in Johannesburg, South Africa were enrolled into a prospective cohort study
(2009–2010). Fertility intentions were assessed at enrollment and at 30-day intervals via an
interviewer-administered questionnaire. We used group-based trajectory modelling to identify
longitudinal patterns of fertility intentions over 12 months. We identified four patterns of fertility
intentions, which we labelled “consistently low” (representing ∼60% of the population), “low and
increasing” (∼23%), “high and increasing” (∼12%), and “high and decreasing” (∼5%). Our
findings suggest that a single family-planning assessment at one time point is insufficient to fully
identify and meet the reproductive needs of women with HIV. As HIV testing and treatment
evolve in South Africa, routine screening for fertility intentions can offer important opportunities
to optimize HIV treatment, prevention, and maternal and child health.
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Introduction
Understanding reproductive goals and fertility inten-
tions is important for optimizing the health of women
and their children, including HIV treatment and preven-
tion among couples affected by HIV. For women living
with HIV wanting to avoid pregnancy, contraceptive
counselling and care can minimize pregnancy-related
morbidity and mortality, including mother-to-child
transmission (Calvert & Ronsmans, 2013; Newell et al.,
2004; Reynolds, Janowitz, Homan, & Johnson, 2006;
Reynolds, Janowitz, Wilcher, & Cates, 2008; UNAIDS,
2015; Wilcher, Petruney, Reynolds, & Cates, 2008). For
women and couples affected by HIV who desire a
baby, safer conception services can help to ensure pre-
conception viral suppression, which prevents both sexual
transmission of HIV to uninfected partners and vertical
transmission to infants (Bekker et al., 2011; Matthews
et al., 2018; Schwartz et al., 2017, 2014).
Data from Botswana further underscore the impor-
tance of comprehensively assessing and addressing
women’s reproductive health needs within HIV
treatment programmes. Preliminary findings from
the Tsepamo Study indicated that women who con-
ceive while taking dolutegravir may experience an
increased risk for neural-tube defects in their new-
borns (Zash, Makhema, & Shapiro, 2018). The
World Health Organization (WHO), the United States
Food and Drug Administration, and the European
Medicines Agency’s Pharmacovigilance Risk Assess-
ment Committee responded with a renewed focus on
limiting dolutegravir use for women intending to
become pregnant (European Medicines Agency, 2018;
United States Food and Drug Administration, 2018;
WHO, 2018). While recent date are more reassuring,
prompting WHO to now recommend the use of
dolutegravir for pregnant women and those of child-
bearing potential (WHO, 2019), the prevalence of
neural-tube defects remains greater in association
with dolutegravir exposure than with other types of
antiretrovirals (Zash, Holmes, et al., 2019).
Routine screening for fertility intentions during HIV
treatment visits represents a potential opportunity to
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identify and meet the family planning needs of women
living with HIV. Changes in life circumstances or health
status may rapidly shift both short-term and long-term
reproductive goals over the life course, irrespective of
HIV status (Taulo et al., 2009; Yeatman, Sennott, & Cul-
pepper, 2013). In general, few data have explored longi-
tudinal changes in fertility intentions, particularly in sub-
Saharan Africa (Kodzi, Casterline, & Aglobitse, 2010;
Sennott & Yeatman, 2013). In South Africa, fertility
intentions are infrequently assessed after initial antire-
troviral therapy (ART) enrollment (Schwartz, Mehta, et
al., 2012), and practical guidance and messaging around
comprehensive assessment of fertility intentions remain
sparse. New strategies are urgently needed to link
women living with HIV to appropriate contraceptive
and safer conception services (Black & Schwartz, 2018).
We have previously shown among women living with
HIV in South Africa that unmet need for contraception
can rapidly increase or decrease (Rucinski et al., 2018),
indicating the need for routine monitoring of contracep-
tive needs to prevent unintended pregnancies and associ-
ated adverse events. In the current study, we examine
trajectories of fertility intentions to assess the extent to
which pregnancy desires and the corresponding need
for safer conception and ART regimen selection vary
over time.
Methods
Data were collected from a prospective cohort study of
12-month pregnancy incidence in HIV-positive women
on ART. Detailed study procedures and eligibility criteria
have been previously reported (Schwartz, Mehta, et al.,
2012; Schwartz, Rees, et al., 2012; Schwartz, Taha, et
al., 2012; Steiner, Black, Rees, & Schwartz, 2016; Rucinski
et al., 2018, 2019). Briefly, 850 HIV-infected women on
or initiating ART were recruited from four public-sector
HIV outpatient clinics in Johannesburg and followed for
12 months between 2009 and 2011. Women were eligible
for participation if they were 18–35 years old, not preg-
nant or breastfeeding and had not given birth in the last
three months. Women with an infertility diagnosis and
those who previously had a tubal ligation, hysterectomy
or bi-lateral oophorectomy were ineligible. Study staff
assessed pregnancy through urine-based pregnancy test-
ing (One Step hCG Urine Pregnancy Test, Atlas Link
Technology, Beijing). ART regimen, CD4 cell count
and HIV viral load were confirmed through medical
record review. After providing written informed consent,
eligible women completed an interviewer-administered
questionnaire assessing demographic and behavioural
characteristics. Fertility intentions were measured at
enrollment using three questions that asked about
current and future childbearing plans. Women were
first asked if they were currently trying to conceive at
the time of interview (yes/no). Those answering “no”
to the first question were asked if they planned to con-
ceive in the next 12 months (yes/no/not sure). Those
answering “no” or “not sure” to this second question
were then asked if they desired a baby at some point in
the future (yes/no/not sure). Follow-up visits occurred
every 1–3 months during routine clinic visits, during
which women provided updated information on whether
they were currently trying to conceive (yes/no).
We constructed an analytic cohort in which we fol-
lowed each woman from enrollment through 12 months
of follow-up. We assessed current fertility intentions
dichotomously every month for a total of up to 12
time points; women were considered as either actively
trying to conceive or not within each month at which
they had a visit. If a woman attended more than one rou-
tine HIV clinical care visit in a given month, correspond-
ing to multiple assessments of fertility intentions in that
month, we used her assessment of fertility intentions
from the first visit only. Women without a visit in a
given month were assigned a missing value for that
month. Women with only an enrollment visit were
excluded; the remaining women were censored at preg-
nancy, complete loss to follow-up, or the end of 12
months.
We used group-based trajectory modelling, which
facilitates identification of latent groups of individuals
whose outcomes of interest follow a similar trajectory
over time (Nagin, 2005; Nagin & Odgers, 2010) to
describe population patterns of fertility intentions over
12 months. We first fit a series of trajectory models to
identify the most appropriate number of trajectory
groups, considering up to five groups to allow for hetero-
geneity while maintaining interpretability. These models
were fit using cubic polynomial terms, and the Bayesian
Information Criterion (BIC) was used to select the trajec-
tory model with the best fit (Nagin, 2005). After the best-
fitting number of trajectories was selected, we then con-
sidered constant, linear, quadratic, and cubic specifica-
tions for each trajectory group, selecting a final model
through visual inspection of the data and using the BIC.
Once we identified a final model, we assigned each
woman in the cohort to a trajectory group using a maxi-
mum probability assignment rule, where each woman
was categorized in the trajectory group for which her
posterior probability was highest. To assess model ade-
quacy, we examined the mean of the posterior probabil-
ities of group membership, ensuring the mean was ≥0.70
for each group (Nagin, 2005). We then used descriptive
profiles to summarize characteristics (captured at enroll-
ment) for women in each group.
In sensitivity analyses,we re-estimated trajectories using
quarterly assessments of fertility intentions, using the first
visit within a given three-month period if women hadmul-
tiple measurements in that quarter. We did this to account
for missing observations, which resulted primarily from
our choice to finely measure fertility intentions every
monthwithin an existing research programmewhere visits
more or less every three months were standard. All models
were fit using PROCTRAJ (https://www.andrew.cmu.edu/
user/bjones/index.htm), a free downloadable SAS add-on
package (SAS, version 9.4, Cary, NC).
Results
Overall, 850 HIV-positive women were enrolled.
Twenty-one (2.5%) women completed a fertility inten-
tions assessment at enrollment but did not return after
their initial study visit and were thus excluded from
further analyses (S1 Table). Among the remaining 829
women, median time on ART was 13 months (IQR 5,
24). Most women were in a relationship (93%) with a
spouse, boyfriend, or regular sexual partner. Nearly all
(92%) had previously been pregnant. Nearly half (43%)
reported plans to conceive in the next 12 months; 12%
were trying to conceive at enrollment.
In longitudinal analyses, a four-group model emerged
as the best-fitting model to describe temporal patterns of
fertility intentions over 12 months (Figure 1). Model fit
statistics are presented in the supplemental materials
(S2 Table). An estimated 60% of women were predicted
to have a consistently low probability (between 0% and
3%) of trying to conceive over the study period. An esti-
mated quarter (23%) were predicted to have a low but
increasing probability (from 3% at enrollment to 47%
at month 12), and an estimated 5% were predicted to
have a high then decreasing probability (from 57% to
∼85% over the first six months to <1% at month 12).
Finally, an estimated 12% of women were predicted to
have a consistently high – and increasing – probability
of trying to conceive (from 64% at enrollment to 99%
at month 12). We labelled these fertility intentions
trajectories as “consistently low”, “low and increasing”,
“high then decreasing”, and “high and increasing”,
respectively.
Based on the maximum posterior probability assign-
ment rule, 552 (67%) women were assigned to the con-
sistently low group, 141 (17%) to the low and
increasing group, 106 (13%) to the high and increasing
group, and 30 (4%) to the high then decreasing group
(Table 1). These percentages were similar to the trajec-
tory group sizes estimated from the model’s parameters.
For all groups, the mean posterior probability of group
membership was >0.80 and the median number of fol-
low-up visits was ≥7 (Table 1).
Figure 1. Predicted trajectories of fertility intentions for 829 women living with HIV in South Africa between 2009 and 2011. Points
represent the observed proportions of women trying to conceive among those assigned to a given trajectory group on the basis of
their maximum posterior group membership probability. Curves represent the proportion of women trying to conceive as estimated
by the model for a given trajectory group and corresponding 95% confidence intervals (dashed lines). The “consistently low” and “high
then decreasing” trajectories were each modelled using a quadratic term, and the “low and increasing” and the “high and increasing”
trajectories each using a cubic term.
Women assigned to the consistently low fertility
intentions group had more recently given birth (median
time since last birth: 36 months) compared to women
assigned to the other three groups (low and increasing:
median of 60 months; high and increasing: median of
72 months; high then decreasing: median of 64 months)
(Table 1). More than a third (37%) of women assigned to
the consistently low group had been pregnant at their
initial HIV diagnosis, compared to 26% assigned to the
low and increasing group, 16% assigned to the high
and increasing group, and 17% assigned to the high
then decreasing group. Most (87%) women assigned to
the consistently low group had one or more living chil-
dren, compared to 66%, 61%, and 47% of women
assigned to the low and increasing, high and increasing,
and high then decreasing groups, respectively. The per-
centage of women planning to conceive in the next
year (as reported at enrollment) was lowest (27%)
among those whose fertility intentions patterns led to
assignment in the consistently low group, intermediate
(56%) among those assigned to the low and increasing
group, and highest (97%) among those assigned to the
high and increasing or high then decreasing group.
The percentage of women reporting hormonal contra-
ceptive use at enrollment followed a roughly opposite
pattern across these four groups (consistently low:
33%, low and increasing: 16%, high and increasing: 9%,
high then decreasing: 13%).
In sensitivity analyses where we re-estimated trajec-
tories using quarterly assessments, three trajectory
groups emerged (S3 Figure). Results were broadly similar
to those found in the main analysis, insofar as women
predominantly were predicted to have a consistently
low probability of trying to conceive, but an estimated
quarter were predicted to have fertility intentions that
changed over time.
Discussion
Supporting women living with HIV to safely realize their
reproductive goals is important for HIV prevention and
for women’s and children’s health more broadly. In this
prospective cohort of South African women living with
HIV, we found that although 60% of women reported
consistently low fertility intentions, considerable changes
in fertility intentions were seen in a sizeable subset of the
cohort, even within a brief, 12-month period. Our
findings affirm that routine assessment of fertility inten-
tions during HIV clinical care visits should be prioritized
Table 1. Characteristics at enrollment of 829 women assigned to “consistently low”, “low and increasing”, “high and increasing”, and
“high then decreasing” trajectories of fertility intentions over 12 monthsa.
Consistently
low
N = 552
(66.6%)
Low and
increasing
N = 141 (17.0%)
High and
increasing
N = 106 (12.8%)
High then
decreasing
N = 30 (3.6%)
Mean SD Mean SD Mean SD Mean SD
Posterior probability of group
membership
0.90 0.09 0.93 0.12 0.82 0.18 0.85 0.17
Median IQR Median IQR Median IQR Median IQR
Monthly follow-up visits 7.0 6–8 7 6–9 8 7–9 7 6–9
Age (years) 30.7 28–33 30.4 26–33 30.1 27–33 29 27–30
No. living children 1.0 1–2 1 0–1 1 0–1 0 0–1
Months since last pregnancy 36.0 15–84 60 24–96 72 30–108 64 20–108
CD4 count at enrollment (cells/µl) 326.0 195–475 256 169–404 295.5 172–460 291.5 153–410
Months on ART 14.2 6–27 8.6 3–20 11.1 5–22 6.5 4-18
n % n % n % n %
Married/cohabitating with a partner 231 41.9 61 43.3 64 60.4 12 40.0
In a relationshipb 506 91.7 128 90.8 105 99.1 30 100
Pregnant at HIV diagnosis 204 37 36 25.5 17 16 5 16.7
Any living children 481 87.1 93 66 65 61.3 14 46.7
Trying to conceive, currently 10 1.8 4 2.8 70 66 18 60.0
Planning to conceive, next yearc 148 26.8 79 56 103 97.2 29 96.7
Planning to conceive, everd 18 85.7 130 92.2 106 100 30 100
Main partner desires a/another childe 315 70.3 110 94.8 97 97 30 100
Taking hormonal contraception 183 33.2 22 15.6 9 8.5 4 13.3
Fell pregnant during follow-up 102 18.5 20 14.2 25 23.6 2 6.7
Abbreviations; SD: Standard Deviation, IQR: Interquartile Range, ART: Antiretroviral therapy, No.: Number.
aEach woman was assigned to either the consistently low, low and increasing, high and increasing, or high then decreasing trajectory group using a maximum-
probability assignment rule.
bComprises women who were married/cohabitating with a partner, as well as those women who reported a boyfriend or regular sexual partner.
cWomen who planned to conceive “in the next year” comprised those who reported they were already trying to conceive at enrollment and those who reported
they were planning to conceive in the next 12 months.
dWomen who planned to conceive “ever” comprised those who reported they were already trying to conceive at enrollment, those who reported they were
planning to conceive in the next 12 months, and those who reported they desired a baby at some point in the future.
eExcludes women who were uncertain about their partner’s fertility intentions.
by HIV care providers to meet the contraceptive and
safer conception needs for women living with HIV.
Though fertility intentions are generally recognized as
being dynamic among women of reproductive age, few
prior studies have assessed changes in fertility intentions
over time among women living with HIV (Hoffman
et al., 2008; Taulo et al., 2009). Furthermore, despite
national recommendations to provide integrated family
planning and HIV treatment services (Republic of
South Africa Department of Health, 2012), fertility
intentions are not routinely screened within ART ser-
vices in South Africa. This lack of routine screening rep-
resents a critical gap in HIV prevention programming.
We elucidate the potential size of this gap, estimating
that nearly one-third of women had a marked increase
over only 12 months in their predicted probability of try-
ing to conceive.
Routine assessment of fertility intentions may offer an
important opportunity for providers to mitigate HIV
transmission risks by encouraging viral suppression
and considering ART regimen switches if needed. As
findings from Botswana still indicate a potential safety
signal between dolutegravir taken at the time of con-
ception and neural-tube defects, many countries have
delayed or limited roll-out of dolutegravir to women or
subsets of women while emphasizing the importance of
contraceptive use for women of childbearing age. Pre-
viously, mixed messages around regimen management
related to fears/signals of teratogenicity have resulted
in irregular regimen management for women (Black &
Schwartz, 2018; Schwartz, Taha, et al., 2012). Our
findings indicate that a single assessment of childbearing
plans at ART enrollment is likely insufficient to guide
decisions around regimen switching, as women’s fertility
intentions may change, even over a 12-month period.
Moreover, while characteristics of women assigned to
each trajectory group differed in some instances, particu-
larly with respect to measures of childbearing experience
and the timing of HIV diagnosis, these differences should
not be used to direct screening in clinical practice.
Instead, routinely asking all women for updates on
their childbearing plans each time they present to
care – both for the immediate future and over the next
year – may offer a measurable indication for pre-con-
ception health optimization and safer conception coun-
selling, including ensuring viral load monitoring is up
to date.
This study has some limitations. Estimated trajec-
tories reflect specifically the fertility intentions of
women enrolled in this study, as the fertility intentions
of partners were not assessed during follow-up. To the
extent that decisions around childbearing reflect the fer-
tility intentions of both women and their partners, the
lack of information about partner intentions may limit
our understanding of drivers behind the trajectories pre-
sented here. Approximately three percent of women did
not return after their initial study visit, and although
most characteristics of this small group of excluded
women were similar to those included in trajectory ana-
lyses, their patterns of fertility intentions may have
differed. Trajectories of fertility intentions may also
have been more or less dynamic among women who
reported to the clinic with less frequency, and for
whom monthly assessments of fertility intentions were
not fully observed. However, in sensitivity analysis
where we used wider intervals (every three months)
that resulted in less missing data, trajectories were gener-
ally similar. Our choice to classify women into trajec-
tories for which their posterior probability of group
membership was highest does not fully account for
uncertainty in assignment (Clogg, 1995), and while this
approach minimizes the number of incorrect assign-
ments compared to other approaches (Goodman,
2007), some classification error may have occurred
(Bray, Lanza, & Tan, 2015) in our descriptive presen-
tation of group profiles. However, the mean of the pos-
terior probabilities of group membership was generally
high for each group, suggesting good assignment accu-
racy, and the proportion of women assigned to each
group closely corresponded to the groups’ estimated
probability from the model’s parameters. While the
inclusion of multivariable analysis of potential predictors
was beyond the scope of this brief manuscript, formal
predictive modelling that characterizes distinct predic-
tors of changing fertility intentions may be appropriate
for future research. We were also not able to confirm
the original treatment indication among ART-experi-
enced women in this study, and non-pregnant women
were only eligible for lifelong ART initiation with a
CD4 count ≤200 cells/ml or WHO clinical stage 4 diag-
nosis at the time of enrollment. It is possible that trajec-
tories of fertility intentions may differ in the current
“treat all” era, and future studies should explore any tem-
poral changes.
Despite these limitations, our findings strongly suggest
that women living with HIV have diverse reproductive
goals and needs that may change over the short-term.
Routine assessment of fertility intentions – both at initial
care presentation and throughout the HIV treatment pro-
cess – can increase contraceptive use, referrals for safer
conception counselling provision, and ART regimen
changes as appropriate. As HIV testing and treatment
evolve in South Africa, routine screening for fertility
intentions can better direct care delivery, offering impor-
tant opportunities to optimize HIV prevention and
maternal and child health outcomes in this population.
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